Galectin-3 binds to β-galactoside and thus to glycosylated Natural killer (NK) and T-cell surface receptors thereby inducing impairment of NK cell activity and anergy of tumor infiltrating CD8 lymphocytes (CD8 TIL) in cancer (19–22). Here, CD8A is linked to neoplasm.